The estimated Net Worth of Randall Mack is at least $24.4 mil dollars as of 1 December 2016. Mr Mack owns over 6,100 units of Recro Pharma Inc stock worth over $24,357 and over the last 11 years he sold REPH stock worth over $0.
Mr has made over 2 trades of the Recro Pharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 6,100 units of REPH stock worth $12,749 on 1 December 2016.
The largest trade he's ever made was exercising 6,100 units of Recro Pharma Inc stock on 1 December 2016 worth over $12,749. On average, Mr trades about 623 units every 15 days since 2014. As of 1 December 2016 he still owns at least 11,654 units of Recro Pharma Inc stock.
You can see the complete history of Mr Mack stock trades at the bottom of the page.
Randall J. Mack is the Sr. VP of Devel. at Recro Pharma Inc.
Mr Mack is 56, he's been the Sr. VP of Devel. of Recro Pharma Inc since . There are 6 older and 3 younger executives at Recro Pharma Inc. The oldest executive at Recro Pharma Inc is Winston Churchill, 79, who is the Independent Director.
Randall's mailing address filed with the SEC is 490 LAPP ROAD, , MALVERN, PA, 19355.
Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm y James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.
Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
Recro Pharma Inc executives and other stock owners filed with the SEC include: